Media Newsroom of

Stemedica International SA

Route de la Corniche 9A
Epalinges, Vaud - 1066 Switzerland
Phone: 41216519050
Website: http://stemedica-intl.com

Founded in Epalinges, Switzerland, in 2008, Stemedica International S.A. is a biotechnology company that develops therapeutic applications for the treatment and prevention of Alzheimer’s disease, vascular dementia and Diabetes. The company is a subsidiary of Stemedica Cell Technologies, Inc., a global biotechnology company that manufactures adult allogeneic stem cells. Stemedica International has an exclusive license to manufacture and distribute the parent company’s allogeneic, ischemia-tolerant mesenchymal stem cell (itMSC) and ischemia-tolerant neural stem cell (itNSC) lines and stem cell factors for Alzheimer’s disease and vascular dementia indications. The company also has Swissmedic licenses to import, export and distribute Stemedica Cell Technologies’ cell lines worldwide for human use in approved clinical trials. Manufactured in compliance with cGMP standards, the stem cell lines have a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability.

Stemedica International Discovers Connection between Gut Microbiome and Alzheimer's Disease (AD)

A groundbreaking scientific article titled "Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota" was published 8 February 2017 in Scientific Reports, a Nature Research journal. The preclinical research was conducted at École Polytechnique…

Stemedica International, SA Wins "Favorit" Entrepreneurship 2016 Award in Switzerland

Stemedica International, S.A., a Swiss company that uses its proprietary allogeneic stem-cell therapies for Alzheimer's disease, announces that it has won the coveted Favorit Swiss Entrepreneurship 2016 Award. The event was held at the Beau-Rivage Palace in Lausanne. It was…

Society for Neuroscience (SfN) Selects Stemedica International's Research as a Hot Topic

Stemedica International, SA, a leader in the development of innovative stem cell-based treatments for Alzheimer's disease (AD), is pleased to announce it will share its latest preclinical data at the Society for Neuroscience 46th Annual Conference held from November 12-16…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login